Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

First-Line Ovarian Cancer Approval Solidifies Lead For AstraZeneca's Lynparza

Dec 19 2018

• By Emily Hayes

Related Content

FDA Finally Approves Avastin In First-Line Ovarian Cancer

Jun 13 2018

Stellar Survival Data For AZ's Lynparza Hailed At ESMO

Oct 22 2018

GSK Embraces PARP Promise With Tesaro Buy

Dec 03 2018

AZ's Lynparza PARP Lead Likely To Lengthen With FDA Priority Review

Nov 12 2018

Ovarian Cancer Market Snapshot: AstraZeneca's Lynparza Poised To Lead In Niche Space

Dec 07 2018

Related Companies

AstraZeneca PLC

Merck & Co., Inc.

Clovis Oncology, Inc.

Tesaro, Inc.

Roche Holding AG

GSK plc

Pfizer Inc.

Merck KGaA

Additional Topics

Approvals Research & Development Cancer BioPharmaceutical

More from New Products

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window